Regen BioPharma, Inc. (OTCMKTS:RGBP – Get Free Report) was the recipient of a large growth in short interest in July. As of July 31st, there was short interest totaling 9,516 shares, a growth of ? from the July 15th total of 0 shares. Based on an average daily volume of 95,837,372 shares, the short-interest ratio is currently 0.0 days.
Regen BioPharma Trading Down 50.0%
OTCMKTS:RGBP opened at $0.00 on Monday. Regen BioPharma has a 52-week low of $0.00 and a 52-week high of $0.05.
Regen BioPharma Company Profile
Regen BioPharma, Inc is a development?stage biotechnology company focused on advancing regenerative medicine and immunotherapy products through stem cell science. The company’s research efforts center on identifying and developing novel therapeutic candidates that harness the regenerative potential of adult and embryonic stem cells, with an emphasis on cancer, infectious and autoimmune diseases.
Its primary activities include the discovery and preclinical validation of stem cell?derived receptors and peptides, the development of immuno?oncology assets, and the filing of investigational new drug (IND) applications to support first?in?human studies.
See Also
- Five stocks we like better than Regen BioPharma
- These 5 Dividend Stocks Show Why Income Investing Still Matters
- The Quantum Race Is Heating Up—And 2 Small Players Stand Out
- 3 Robotics Stocks Under $10: Value, Momentum, or Bet?
- 3 ETFs Built to Protect Your Money if the Bull Market Breaks
Receive News & Ratings for Regen BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regen BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
